Russia Diabetic Retinopathy Market Size, Share, and COVID-19 Impact Analysis, By Type (Proliferative Diabetic Retinopathy, and Non-proliferative Diabetic Retinopathy), By Treatment (Anti-VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy), and Russia Diabetic Retinopathy Market Insights, Industry Trend, Forecasts to 2035

Russia Diabetic Retinopathy Market Insights Forecasts to 2035

• The Russia Diabetic Retinopathy Market Size Was Estimated at USD 171.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 8.42% from 2025 to 2035
• The Russia Diabetic Retinopathy Market Size is Expected to Reach USD 417.4 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Russia Diabetic Retinopathy Market Size is anticipated to reach USD 417.4 Million by 2035, Growing at a CAGR of 8.42% from 2025 to 2035. The diabetic retinopathy market in Russia is driven by rising diabetes prevalence, an aging population, better ocular diagnostics, more access to anti-VEGF treatments, rising healthcare spending, and greater awareness of early retinal screening.

Market Overview

The Russia diabetic retinopathy market refers to the ecosystem of diagnostic tools, pharmaceuticals, laser devices, and surgical solutions used to detect, manage, and treat retinal damage caused by diabetes. The market provides support for three main activities which include executing initial screening processes, tracking disease progression and conducting therapies that protect vision through anti-VEGF injections and laser photocoagulation. The applications support operations in hospitals, ophthalmology clinics and specialty centers by providing medical professionals with the tools they need to deliver prompt treatment which helps their diabetic patients maintain eye health and achieve better results throughout their diabetes related medical journey.

The Russian government supports the Federal Project "Fight Against Diabetes" through funding of approximately 30 billion RUB until 2025 which the project uses to develop screening and diagnostic facilities and treatment centers that provide eye care services for diabetic retinopathy complications. The Cabinet allocated approximately 5.5 billion RUB to support regional diabetes programs which improve early detection and care access throughout the country.

The Russian market for diabetic retinopathy has advanced diagnostic capabilities through AI technologies which use a Skoltech neural-network system that achieves more than 97 percent accuracy for automatic retinal analysis and through AI research conducted at the NMIC Endocrinology database initiative. The upcoming possibilities for development will come from increased use of AI screening systems and the growth of tele-ophthalmology and the integration of these systems into national diabetes treatment programs.

Report Coverage

This research report categorizes the market for the Russia diabetic retinopathy market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Russia diabetic retinopathy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Russia diabetic retinopathy market.

Driving Factors

The diabetic retinopathy market in Russia is driven by the increasing diabetes rates, the aging population, and the rising number of people developing vision problems. The market expansion receives support through three factors which include government sponsored diabetes initiatives and improved access to eye diagnostic tools and the increasing use of anti-VEGF medications and laser treatment methods. The demand for prompt diagnosis and successful disease control measures receives a boost from three factors which include AI-driven retinal screening technology improvements and better healthcare system development and increased public knowledge about the need for early eye tests.

Restraining Factors

The diabetic retinopathy market in Russia is mostly constrained by the restricted access to high-level eye care services in remote areas and the expensive nature of medical treatments and the lack of qualified medical practitioners and difficulties in obtaining reimbursement and the slow process of diagnosis which results from patients having low knowledge of the condition and irregular screening processes.

Market Segmentation

The Russia diabetic retinopathy market share is classified into type and treatment.

• The proliferative diabetic retinopathy segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Russia diabetic retinopathy market is segmented by type into proliferative diabetic retinopathy, and non-proliferative diabetic retinopathy. Among these, the proliferative diabetic retinopathy segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is mostly because PDR is the disease's severe, vision-threatening stage, necessitating expensive treatments including vitrectomy, laser photocoagulation, and anti-VEGF injections. Due to a lack of frequent screening, many patients in Russia receive their diagnoses later than they should, which increases the number of severe cases. Consequently, PDR's larger revenue share is driven by higher treatment volumes and per-patient spending.

• The anti-VEGF drug segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. 

The Russia diabetic retinopathy market is segmented by treatment into anti-VEGF drug, steroid implants, laser surgeries, and vitrectomy. Among these, the anti-VEGF drug segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Because it is the first-line treatment for both proliferative disease and diabetic macular edema, requires repeated injections, is commonly used in hospitals, and has the greatest per-patient spending, which drives the largest revenue share, anti-VEGF therapy leads the market among these.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Russia diabetic retinopathy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Fyodorov Eye Microsurgery Complex
• S. Fyodorov Eye Microsurgery Federal State Institution
• Ufa Research Institute of Eye Diseases
• Medicina Clinic
• Clinical Hospital No 85 of FMBA of Russia
• National Medical Surgical Center
• OkoMed Eye Clinic
• Pharmstandard
• Promomed Group
• Solopharm
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In October 2025, PSK Pharma registered ranibizumab PSK, a novel ranibizumab retinal therapeutic product, in Russia for neovascular disorders and proliferative diabetic retinopathy, increasing the availability of local treatments.

• In June 2025, Russian ophthalmology journals released clinical pieces on the pathophysiology of proliferative diabetic retinopathy, showcasing regional research efforts.

• In March 2025, Skoltech and AIRI researchers' AI-driven retinal diagnosis tool started demonstrating automation of retina scan analysis to expedite the detection of diabetic retinopathy.

Market Segment

This study forecasts revenue at the Russia, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Russia diabetic retinopathy market based on the below-mentioned segments:

Russia Diabetic Retinopathy Market, By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

Russia Diabetic Retinopathy Market, By Treatment

• Anti-VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy